Dawson James Starts Collplant Holdings Inc. (CLGN) at Buy

Dawson James analyst Jason Kolbert initiates coverage on Collplant Holdings Inc. (NASDAQ: CLGN) with a Buy rating and a price target of $9.00.

The analyst commented, "CollPlant is a bioengineering company developing, manufacturing, and commercializing regenerative medicine products. CollPlant’s focus is on its proprietary technology platform, which mass produces recombinant human collagen (rhCollagen) sourced from tobacco plants. CollPlant uses this rhCollagen to 3d bioprint tissues, organs, and other medical aesthetic products. CollPlant currently has a Strategic agreement with United Therapeutics (NASDAQ: UTHR) for 3D bioprinting of lung transplants and other life-saving organs. Multiple other partners are expected to emerge over the next few years."

For an analyst ratings summary and ratings history on Collplant Holdings Inc. click here. For more ratings news on Collplant Holdings Inc. click here.

Shares of Collplant Holdings Inc. closed at $4.67 yesterday.

You May Also Be Interested In

• HSBC Starts Auna SA (AUNA) at Buy, 'Just what the doctor prescribed'
• KLA Corporation (KLAC) PT Raised to $725 at Citi
• Loop Capital Starts MongoDB (MDB) at Buy, '2H Ramp Ahead'